Table 3.
Newcastle-Ottawa Scale quality assessment of included studies
Study | Selection | Comparability | Outcome | Newcastle Ottawa Score Total | ||||
---|---|---|---|---|---|---|---|---|
Representativeness of the sample (true representation of target population) | Sample size (justified and satisfactory) | Non-participants (respondents vs. non respondents and response rate) | Ascertainment of the exposure (BP measurement method) | Comparability of groups on basis of design or analysis (study controls for important factors such as BP, age, gender, anti-hypertensive medication use) | Assessment of the outcome (PH as n/N and/or %) | The outcome is presented in full (no unexplained omissions from dataset) | ||
Alli 1992 [34] | * | * | / | * | * | ** | * | 7 |
Assantachai 1998 [58] | * | * | / | * | ** | ** | * | 8 |
Atli 2006 [35] | * | / | / | * | / | ** | * | 5 |
Bell 2016 ARIC [59] | * | * | * | * | ** | ** | * | 9 |
Bell 2016 CHS [59] | * | * | * | * | ** | ** | * | 9 |
Bengtsson Lindberg 2015 [36] | * | * | / | * | * | ** | * | 7 |
Bouhanick 2014 [25] | * | * | / | * | ** | ** | * | 8 |
Cilia 2015 [60] | / | * | / | * | * | ** | / | 5 |
Clara 2007 [10] | * | * | / | * | / | * | * | 5 |
Cohen 2015 [11] | * | * | / | * | / | ** | * | 6 |
Cremer 2017 [47] | * | * | / | * | ** | ** | * | 8 |
Curreri 2016 [61] | * | * | / | ** | ** | ** | * | 9 |
Drozdz 2016 [48] | / | / | / | ** | / | ** | * | 5 |
Enrique Asensio 2011 [23] | * | * | / | ** | / | ** | * | 7 |
Ensrud 1992 [62] | / | * | / | * | ** | ** | * | 7 |
Fan 2010 [63] | * | * | * | * | ** | ** | * | 9 |
Fedorowski 2010 [64] | * | * | * | / | ** | ** | * | 8 |
Fleg 2016 [26] | / | * | * | * | ** | ** | * | 8 |
Foster-Dingley 2018 [49] | * | * | / | * | ** | ** | * | 8 |
Frewen 2014 [65] | * | * | / | / | ** | ** | * | 7 |
Gangavati 2011 [66] | * | * | / | ** | * | ** | * | 8 |
Hiitola 2009 [50] | * | * | * | ** | ** | ** | * | 10 |
Hiorth 2019 [37] | * | * | * | * | * | ** | * | 8 |
Hirai 2009 [27] | * | * | * | ** | ** | ** | * | 10 |
Hommel 2016 [22] | * | / | / | ** | ** | ** | * | 8 |
Kamaruzzaman 2010 [38] | * | * | * | * | * | ** | * | 8 |
Kartheek 2011 [51] | / | / | / | * | / | ** | * | 4 |
Klanbut 2018 [28] | * | / | / | * | ** | ** | * | 7 |
Kleipool 2019 [29] | * | * | / | * | ** | ** | * | 8 |
Lampela 2013 [67] | * | * | / | * | * | ** | / | 6 |
Liepelt Scarfone 2015 [39] | * | * | / | * | ** | ** | * | 8 |
Liu 2016 [40] | * | * | / | / | ** | ** | * | 7 |
Luukinen 1999 [68] | * | * | * | ** | ** | ** | * | 10 |
Luukkonen 2017 [69] | * | * | * | * | ** | ** | * | 9 |
Mader 1987 [70] | * | * | * | / | * | ** | * | 7 |
Masaki 1998 [71] | * | * | * | * | / | ** | * | 7 |
Masuo 1996 [41] | / | / | / | / | / | ** | * | 3 |
Mendez 2018 [52] | * | * | / | ** | ** | ** | * | 9 |
Merola 2016 [30] | / | * | / | * | * | ** | * | 6 |
Nguyen 2017 [53] | * | * | / | * | * | ** | * | 7 |
O’Connell 2015 [72] | * | * | / | / | ** | ** | * | 7 |
Oishi 2016 [42] | / | / | / | * | ** | ** | * | 6 |
Ong 2017 [73] | * | * | / | / | * | ** | * | 6 |
Perez Orcero 2016 [43] | / | * | / | / | ** | ** | * | 6 |
Putnam 2018 [54] | * | * | * | ** | * | ** | * | 9 |
Rockwood 2012 [55] | * | * | / | ** | * | ** | * | 8 |
Romagnolo 2019 [31] | * | / | * | ** | ** | ** | * | 9 |
Shin 2004 [74] | * | * | * | * | ** | ** | * | 9 |
Sonnesyn 2009 [32] | / | * | / | * | * | ** | / | 5 |
Valbusa 2012 [24] | * | * | / | * | ** | ** | * | 8 |
Vanhanen 1996 [75] | * | * | / | * | * | ** | * | 7 |
Van Hateren 2012 [44] | * | * | / | * | ** | ** | * | 8 |
Velilla Zancada 2017 [76] | * | * | / | * | ** | ** | * | 8 |
Veronese 2014 [56] | * | * | * | ** | ** | ** | * | 10 |
Viramo 1999 [77] | * | * | / | * | * | ** | / | 6 |
Walczak 1991 [45] | / | / | / | * | / | ** | * | 4 |
Wecht 2016 [80] | / | * | / | ** | ** | ** | * | 8 |
Wolters 2016 [57] | * | * | * | * | ** | ** | * | 9 |
Wu 2009 [78] | * | * | / | * | ** | ** | * | 8 |
Yap 2008 [79] | * | * | * | ** | ** | ** | * | 10 |
Zhu 2016 [46] | / | * | * | * | * | ** | * | 7 |